2-(chloromethyl)-5-(3-chlorophenyl)-1,3-oxazole | 64640-15-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(chloromethyl)-5-(3-chlorophenyl)-1,3-oxazole
• CAS: 64640-15-9
• 化学式: C₁₀H₇Cl₂NO
• mdl: MFCD06373945
• 分子量: 228.078
• InChiKey: XREYQNDZYBPWOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(chloromethyl)-5-(3-chlorophenyl)-1,3-oxazole 在 potassium hydroxide 作用下， 以 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 34.0h， 生成 4-([5-(3-chlorophenyl)-1,3-oxazol-2-yl]methylsulfanyl)-6-(4- methylpiperazin-1-yl)-1,3,5-triazin-2-amine
  参考文献：
  名称：

  [EN] AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR
  [FR] AGONISTES DU RÉCEPTEUR 1 D'ACIDE GRAS LIBRE ET LEUR UTILISATION DANS DES MALADIES ASSOCIÉES AUDIT RÉCEPTEUR

  摘要：

  本发明涉及一种新型游离脂肪酸受体（FFAR）激动剂（I），特别是FFAR1的激动剂，以及将所述FFAR激动剂用作药物的用途，特别是用于治疗和/或预防适于增强FFAR1活性的情况或疾病，例如涉及糖血平衡受损、代谢综合征、肥胖症、血脂异常、肾脏疾病、纤维化和硬化疾病以及肝胆疾病的情况或疾病。其中，R1-S-CH2-OXA-R2（I）。

  公开号：

  WO2022083853A1

文献信息

• [EN] HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS<br/>[FR] DÉRIVÉS D'HÉTÉROCYCLYLMÉTHYLIDÈNE ET LEUR UTILISATION EN TANT QUE MODULATEURS DES RÉCEPTEURS MGLUR5
  申请人：RECORDATI IND CHIMICA E FARMACEUTICA SPA

  公开号：WO2019002571A1

  公开（公告）日：2019-01-03

  This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.

  这项发明涉及式(I)的化合物及其作为mGluR5受体活性的变构调节剂的用途，包含这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神疾病的药剂，如精神分裂症或认知能力下降、痴呆症或认知障碍，或其他可能直接或间接与谷氨酸功能障碍相关的病理的方法。
• [EN] OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1<br/>[FR] DÉRIVÉS D'OXAZOLE ET D'OXADIAZOLE UTILES EN TANT QU'AGONISTES DU RÉCEPTEUR 1 D'ACIDES GRAS LIBRES
  申请人：GBIOTECH S A R L

  公开号：WO2020211956A1

  公开（公告）日：2020-10-22

  The present invention relates to novel free fatty acid receptor (FFAR) agonists of general formula (I), in particular agonists of FFAR1, and to the use of said FFAR agonists as medicaments, in particular for treatment and/or prevention of type 2 diabetes mellitus (T2DM), R1-S-CH2-OXA-R2 (l) wherein OXA is selected from the group consisting of 1,3-oxazolyl 1,2,4-oxadiazolyl or 1,3,4-oxadiazolyl, R1 is selected from 1,3,5- triazinyl and pyrimidinyl and R2 is phenyl.

  本发明涉及一种新型自由脂肪酸受体（FFAR）激动剂，其一般式为（I），特别是FFAR1的激动剂，并将所述FFAR激动剂用作药物，特别用于治疗和/或预防2型糖尿病（T2DM），其中OXA选自1,3-噁唑基1,2,4-噁二唑基或1,3,4-噁二唑基的群，R1选自1,3,5-三嗪基和嘧啶基，R2为苯基。
• Phenoxymethyl 1,3-oxazoles and 1,2,4-oxadiazoles as potent and selective agonists of free fatty acid receptor 1 (GPR40)
  作者：Ihor Zahanich、Ivan Kondratov、Vasyl Naumchyk、Yuri Kheylik、Maxim Platonov、Sergey Zozulya、Mikhail Krasavin

  DOI：10.1016/j.bmcl.2015.06.018

  日期：2015.8

  A screening hit that showed a weak (EC50 = 18 mu M), partial agonistic effect on GPR40 was used a prototype for expedited hit expansion effort using a set of advanced building blocks. The latter yielded several 1,3-oxazoles and 1,2,4-oxadiazoles with significantly improved potency (best EC50 = 0.058 mu M). The lead compounds in each chemotype showed a very good ADME profile (aqueous solubility, plasma protein binding, microsomal stability and membrane permeability) and no appreciable inhibition of key cytochromes P450. The compounds reported are significant new starting points for further preclinical development of future diabetic agents with a mechanism of action for which a first-in-class agent is yet to be approved. (C) 2015 Elsevier Ltd. All rights reserved.
• HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS
  申请人：Recordati Industria Chimica E Farmaceutica SPA

  公开号：EP3645521A1

  公开（公告）日：2020-05-06
• OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1
  申请人：Gbiotech S.À.R.L.

  公开号：EP3956323A1

  公开（公告）日：2022-02-23